On February 7, Richard Bernstein, CEO of Richard Bernstein Advisors, joined ‘The Exchange’ on CNBC to discuss the state of equity markets, assessing which stocks are growing fast and trading cheaply.
The 4 generic pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts’ consensus estimates by ...
Ozempic patent expiry has triggered a fresh pharma race in India. Sun Pharma, Cipla, and Dr Reddy’s are among 7 players ...
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40–50% post patent expiry. Three early movers are taking sharply different routes—low-cost, premium, and partnerships in ...
Dr. Reddy's, Sun Pharma, Zydus & others launch branded generics after patent expiry, targeting a ₹12,000-crore market ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the most promising low-cost stocks to buy now. On February 3, Ultragenyx Pharmaceutical announced positive long-term data for UX111, which is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results